Clough Global Equity Fund is a closed ended equity mutual fund launched and managed by Clough Capital Partners, L.P. It invests in public equity markets across the globe. The fund seeks to invest in stocks of companies operating across diversified sectors. It employs fundamental and quantitative analysis with a bottom up stock picking approach to create its portfolio, with focus on factors such as a company's competitive position, quality of company management, quality and visibility of earnings and cash flow, balance sheet strength, and relative valuation. The fund follows a theme-based investment process which involves focusing on such events as industry consolidation, technological change, an emerging shortage of a product or raw material, and changes in government regulations. It benchmarks the performance of its portfolio against the S&P 500 Index. Clough Global Equity Fund was formed on January 25, 2005 and is domiciled in the United States.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company's marketed product includes AMITIZA (lubiprostone), a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. Its product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis. The company is also developing VTS-270, which is in a pivotal Phase 2b/3 trial for the treatment of Niemann-Pick Disease Type C1. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland.

Credit Suisse Group AG, together with its subsidiaries, provides various financial services worldwide. It operates through Swiss Universal Bank, International Wealth Management, Asia Pacific, Global Markets, and Investment Banking & Capital Markets segments. The company offers advisory and financial solutions, such as structured advisory, investment advisory, discretionary asset management, mergers and acquisitions transactions, corporate sales and restructurings, divestitures, takeover defense strategies, equity and fixed income sales, trading, debt and equity securities, spin-offs, debt and equity underwritings, private placements, and derivative products, as well as proprietary and third-party products and services. It also provides traditional and structured lending, payment, foreign exchange, capital goods leasing, trade finance, export finance, factoring, ship and aviation finance services; and fund solutions and fund-linked services. In addition, the company offers investment solutions and services to pension funds, governments, foundations and endowments, corporations, and individuals; and global securities sales, trading and execution, prime brokerage, and investment research services. It operates 401 offices and branches. The company offers its products and services to private, corporate, institutional, ultra-high-net-worth and high-net-worth individuals, small and medium-sized enterprises, institutional clients, and financial institutions, as well as affluent and retail clients. Credit Suisse Group AG was founded in 1856 and is based in Zurich, Switzerland.